Pacira BioSciences' Equity Average fell 883.32% to $742.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $742.5 million, marking a year-over-year decrease of 883.32%. This contributed to the annual value of $824.2 million for FY2024, which is 20.29% up from last year.
Latest data reveals that Pacira BioSciences reported Equity Average of $742.5 million as of Q3 2025, which was down 883.32% from $778.2 million recorded in Q2 2025.
Pacira BioSciences' 5-year Equity Average high stood at $885.7 million for Q2 2024, and its period low was $635.3 million during Q1 2021.
For the 5-year period, Pacira BioSciences' Equity Average averaged around $768.7 million, with its median value being $771.5 million (2023).
As far as peak fluctuations go, Pacira BioSciences' Equity Average soared by 7554.61% in 2021, and later tumbled by 1214.45% in 2025.
Quarter analysis of 5 years shows Pacira BioSciences' Equity Average stood at $724.5 million in 2021, then increased by 6.63% to $772.6 million in 2022, then rose by 10.13% to $850.8 million in 2023, then decreased by 10.21% to $764.0 million in 2024, then decreased by 2.81% to $742.5 million in 2025.
Its Equity Average was $742.5 million in Q3 2025, compared to $778.2 million in Q2 2025 and $788.4 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value